Literature DB >> 2117070

Cytolytic T-lymphocyte responses to respiratory syncytial virus: effector cell phenotype and target proteins.

J A Nicholas1, K L Rubino, M E Levely, E G Adams, P L Collins.   

Abstract

Cytolytic T-lymphocyte (CTL) activity specific for respiratory syncytial (RS) virus was investigated after intranasal infection of mice with RS virus, after intraperitoneal infection of mice with a recombinant vaccinia virus expressing the F glycoprotein, and after intramuscular vaccination of mice with Formalin-inactivated RS virus or a chimeric glycoprotein, FG, expressed from a recombinant baculovirus. Spleen cell cultures from mice previously infected with live RS virus or the F-protein recombinant vaccinia virus had significant CTL activity after one cycle of in vitro restimulation with RS virus, and lytic activity was derived from a major histocompatibility complex-restricted, Lyt2.2+ (CD8+) subset. CTL activity was not restimulated in spleen cells from mice that received either the Formalin-inactivated RS virus or the purified glycoprotein, FG. The protein target structures for recognition by murine CD8+ CTL were identified by using target cells infected with recombinant vaccinia viruses that individually express seven structural proteins of RS virus. Quantitation of cytolytic activity against cells expressing each target structure suggested that 22K was the major target protein for CD8+ CTL, equivalent to recognition of cells infected with RS virus, followed by intermediate recognition of F or N, slight recognition of P, and no recognition of G, SH, or M. Repeated stimulation of murine CTL with RS virus resulted in outgrowth of CD4+ CTL which, over time, became the exclusive subset in culture. Murine CD4+ CTL were highly cytolytic for RS virus-infected cells, but they did not recognize target cells infected with any of the recombinant vaccinia viruses expressing the seven RS virus structural proteins. Finally, the CTL response in peripheral blood mononuclear cells of adult human volunteers was investigated. The detection of significant levels of RS virus-specific cytolytic activity in these cells was dependent on at least two restimulations with RS virus in vitro, and cytolytic activity was derived primarily from the CD4+ subset.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2117070      PMCID: PMC247888     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

Review 1.  The regulation of expression of major histocompatibility complex products.

Authors:  P F Halloran; A Wadgymar; P Autenried
Journal:  Transplantation       Date:  1986-04       Impact factor: 4.939

2.  N protein is the predominant antigen recognized by vesicular stomatitis virus-specific cytotoxic T cells.

Authors:  L Puddington; M J Bevan; J K Rose; L Lefrançois
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

3.  Murine cytotoxic T cells specific to respiratory syncytial virus recognize different antigenic subtypes of the virus.

Authors:  C R Bangham; B A Askonas
Journal:  J Gen Virol       Date:  1986-04       Impact factor: 3.891

4.  Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein.

Authors:  N Elango; G A Prince; B R Murphy; S Venkatesan; R M Chanock; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

5.  Cellular and humoral immunity in recurrent respiratory syncytial virus infections.

Authors:  G W Fernald; J R Almond; F W Henderson
Journal:  Pediatr Res       Date:  1983-09       Impact factor: 3.756

6.  Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity.

Authors:  R A Olmsted; N Elango; G A Prince; B R Murphy; P R Johnson; B Moss; R M Chanock; P L Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

7.  Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus.

Authors:  G A Prince; A B Jenson; V G Hemming; B R Murphy; E E Walsh; R L Horswood; R M Chanock
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

8.  Risk of primary infection and reinfection with respiratory syncytial virus.

Authors:  W P Glezen; L H Taber; A L Frank; J A Kasel
Journal:  Am J Dis Child       Date:  1986-06

9.  Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques.

Authors:  S Chakrabarti; K Brechling; B Moss
Journal:  Mol Cell Biol       Date:  1985-12       Impact factor: 4.272

10.  Differences in antigen presentation to MHC class I-and class II-restricted influenza virus-specific cytolytic T lymphocyte clones.

Authors:  L A Morrison; A E Lukacher; V L Braciale; D P Fan; T J Braciale
Journal:  J Exp Med       Date:  1986-04-01       Impact factor: 14.307

View more
  30 in total

1.  Mapping and characterization of the primary and anamnestic H-2(d)-restricted cytotoxic T-lymphocyte response in mice against human metapneumovirus.

Authors:  Guillermina A Melendi; Fidel Zavala; Ursula J Buchholz; Guy Boivin; Peter L Collins; Steven R Kleeberger; Fernando P Polack
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

2.  Conserved cysteine residues within the attachment G glycoprotein of respiratory syncytial virus play a critical role in the enhancement of cytotoxic T-lymphocyte responses.

Authors:  Guillermina A Melendi; Dowd Bridget; Ana C Monsalvo; Federico F Laham; Patricio Acosta; Maria Florencia Delgado; Fernando P Polack; Pablo M Irusta
Journal:  Virus Genes       Date:  2010-11-04       Impact factor: 2.332

3.  Primary cytotoxic T-cell responses to bovine respiratory syncytial virus in calves.

Authors:  R M Gaddum; R S Cook; L H Thomas; G Taylor
Journal:  Immunology       Date:  1996-07       Impact factor: 7.397

4.  Characterization of a novel respiratory syncytial virus-specific human cytotoxic T-lymphocyte epitope.

Authors:  P J Goulder; F Lechner; P Klenerman; K McIntosh; B D Walker
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

5.  The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin.

Authors:  Fernando P Polack; Pablo M Irusta; Scott J Hoffman; M Paula Schiatti; Guillermina A Melendi; M Florencia Delgado; Federico R Laham; Bhagvanji Thumar; R Michael Hendry; Jose A Melero; Ruth A Karron; Peter L Collins; Steven R Kleeberger
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-14       Impact factor: 11.205

6.  Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus.

Authors:  Y W Tang; B S Graham
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

7.  Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10.

Authors:  M Connors; N A Giese; A B Kulkarni; C Y Firestone; H C Morse; B R Murphy
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

8.  Cell-mediated immune responses of lambs to challenge with bovine respiratory syncytial virus.

Authors:  A K Sharma; Z Woldehiwet
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

9.  Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination.

Authors:  Elaine M Castilow; Steven M Varga
Journal:  Future Virol       Date:  2008       Impact factor: 1.831

10.  Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice.

Authors:  B S Graham; L A Bunton; P F Wright; D T Karzon
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.